Rigel Pharmaceuticals, Inc.
350 articles with Rigel Pharmaceuticals, Inc.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.
-
Rigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia
7/14/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib
-
Rigel Announces Availability of TAVLESSE® (Fostamatinib Disodium Hexahydrate) in Europe
7/9/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Grifols S.A., its collaborative partner in Europe , has launched TAVLESSE ® in Germany and the United Kingdom . It was approved by the European Commission in Janu
-
Rigel to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
6/17/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno , the company's chief financial officer, is scheduled to present a company overview at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020 at 10:30 a.m. Eastern Time . To access the live and subs
-
Rigel to Present Poster Highlighting TAVALISSE at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress
6/11/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE ® (fostamatinib disodium hexahydrate) tablets will be highlighted in a presentation at the Virtual Edition of the 25 th EHA Annual Congress taking place June 11-21, 2020 . The presentation will be made available on the event's web
-
Rigel to Present Four Posters Highlighting IRAK1/4 Inhibitor at the EULAR 2020 E-Congress
6/3/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to R835, the company's investigational IRAK1/4 inhibitor, will be presented in two oral and two poster presentations at the European League Against Rheumatism (EULAR) 2020 E-Congress taking place June 3-6, 2020 . A fifth abstract highlighting R83
-
Rigel to Present at the Jefferies 2020 Virtual Healthcare Conference
5/26/2020
Rigel Pharmaceuticals, Inc. announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 1:30 p.m. Eastern Time.
-
Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.
-
Rigel Reports First Quarter 2020 Financial Results and Provides Business Update
5/5/2020
Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2020, including sales of TAVALISSE® tablets, for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
-
Rigel Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
5/1/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that, due to public health and safety concerns related to the coronavirus ("COVID-19") pandemic, recommendations and orders from federal, state and local authorities, and to support the health and well-being of its stockholders, employees, and others, it will host it
-
Rigel Announces Conference Call and Webcast to Report First Quarter 2020 Financial Results and Business Update
4/27/2020
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2020 financial results after market close on Tuesday, May 5 , 2020. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time ( 1:30pm Pacific Time ) to discuss th
-
Rigel Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
2/27/2020
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2019, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for the treatment of adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
-
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2019 Financial Results
2/20/2020
Rigel Pharmaceuticals, Inc. announced that it will report its fourth quarter and year end 2019 financial results after market close on Thursday, February 27, 2020.
-
Rigel to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/9/2020
Rigel Pharmaceuticals, Inc. announced that Raul Rodriguez, the company's president and CEO, is scheduled to present a company overview at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 7:30am PT in San Francisco, CA..
-
Rigel Announces Chief Commercial Officer Transition
12/17/2019
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that Eldon Mayer has resigned from his position as chief commercial officer effective December 23, 2019, to pursue an opportunity with an emerging company.
-
Top 10 Biotech Bay Companies by Revenue
11/18/2019
The companies included on this list are the top ten companies headquartered in Biotech Bay based on 2018 revenue. -
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
11/15/2019
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency, has adopted a positive opinion for Rigel's Marketing Authorization Application (MAA) for fostamatinib disodium hexahydrate (fostamatinib) for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments.
-
Rigel to Present at Jefferies 2019 London Healthcare Conference
11/13/2019
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019 at 4:40pm GMT.
-
Rigel Announces Upcoming Data Presentations at the 61st ASH Annual Meeting & Exposition
11/7/2019
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets has been accepted for two poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition to be held December 7-10, 2019, in Orlando, FL.
-
Rigel Announces Third Quarter 2019 Financial Results
11/5/2019
Advances development pipeline with new RIP1 inhibitor program initiating a Phase 1 study and positive in-human data from IRAK1/4 inhibitor program